{
    "eid": "2-s2.0-85032489556",
    "title": "Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease",
    "cover-date": "2017-12-15",
    "subject-areas": [
        {
            "$": "General Biochemistry",
            "@code": "1300"
        },
        {
            "$": "General Pharmacology",
            "@code": "3000"
        }
    ],
    "keywords": [
        "Chronic kidney disease",
        "Glomerular filtration rate",
        "Renin-angiotensin system",
        "Vitamin D deficiency"
    ],
    "authors": [
        "Abel Esteves Soares"
    ],
    "citedby-count": 7,
    "ref-count": 52,
    "ref-list": [
        "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization",
        "How does proteinuria cause progressive renal damage?",
        "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis",
        "Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency",
        "Medical progress: Vitamin D deficiency",
        "Vitamin D: A growing perspective",
        "Vitamin D insufficiency",
        "Vitamin D insufficiency",
        "Vitamin D Status of Chronic Kidney Disease Patients Living in a Sunny Country",
        "Risk Factors for Hypovitaminosis D in Nondialyzed Chronic Kidney Disease Patients",
        "Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States",
        "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease",
        "Vitamin D in chronic kidney disease",
        "Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality",
        "Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults",
        "Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: The Troms\u00f8 study",
        "Vitamin D deficiency and supplementation and relation to cardiovascular health",
        "Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease",
        "KHA-CARI guideline: Early chronic kidney disease: Detection, prevention and management",
        "Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy",
        "The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study",
        "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease",
        "K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification",
        "J. Am. Soc. Nephrol.",
        "Serum 25-hydroxyvitamin D, Ethnicity, and Blood Pressure in the Third National Health and Nutrition Examination Survey",
        "Vitamin D levels and patient outcome in chronic kidney disease",
        "Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients",
        "Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans",
        "25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study",
        "Vitamin D Deficiency, Inflammation, and Albuminuria in Chronic Kidney Disease: Complex Interactions",
        "Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial",
        "Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial",
        "Efficacy and safety of paricalcitol therapy for chronic kidney disease: A meta-analysis",
        "Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: A retrospective single center study",
        "Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events",
        "Vitamin D supplementation and mortality risk in chronic kidney disease: A meta-analysis of 20 observational studies",
        "Serum 1,25-dihydroxyvitamin d and the development of kidney dysfunction in a Japanese community: The hisayama study",
        "Chronic kidney disease influences multiple systems: Describing the relationship between oxidative stress, inflammation, kidney damage, and concomitant disease",
        "Estimated GFR, albuminuria, and complications of chronic kidney disease",
        "Active vitamin D treatment for reduction of residual proteinuria: A systematic review",
        "2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)",
        "Renoprotective effects of vitamin D analogs",
        "Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase",
        null,
        "Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes",
        null,
        "Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats",
        null,
        "Suppression of renin-angiotensin gene expression in the kidney by paricalcitol",
        "Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system",
        "Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D",
        "Oral cholecalciferol decreases albuminuria and urinary TGF-\u03b21 in patients with type 2 diabetic nephropathy on established renin-angiotensin- aldosterone system inhibition"
    ],
    "affiliation": [
        {
            "affiliation-city": "Londrina",
            "affilname": "Universidade Estadual de Londrina",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Geelong",
            "affilname": "Deakin University",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Londrina",
            "affilname": "Faculdade Pit\u00e1goras",
            "affiliation-country": "Brazil"
        }
    ],
    "funding": [
        "Fundacion Araucaria"
    ]
}